# Cullen/Frost Bankers, Inc.: financial statements, quarterly

CFR · NYSE · CIK 39263 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cfr.md) · [Financials](/companies/cfr/financials.md) · [Filings](/companies/cfr/filings.md) · [Insiders](/companies/cfr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cfr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [24.5 d](/filings/0000039263-26-000011.md) | [24.8](/filings/0000039263-25-000058.md) | [26.1](/filings/0000039263-25-000101.md) | [27.4](/filings/0000039263-25-000117.md) | [27.9 d](/filings/0000039263-26-000011.md) | [28.6](/filings/0000039263-26-000035.md) | [29.2](/filings/0000039263-26-000046.md) | [31.4](/filings/0000039263-26-000056.md) | [32.4 d](/filings/0000039263-26-000011.md) | [32.2](/filings/0000039263-26-000035.md) | [34.2](/filings/0000039263-26-000046.md) | [36.3](/filings/0000039263-26-000056.md) |
| Interest expense | $m | [191 d](/filings/0000039263-24-000013.md) | [195](/filings/0000039263-25-000058.md) | [200](/filings/0000039263-25-000101.md) | [204](/filings/0000039263-25-000117.md) | not reported | [169](/filings/0000039263-26-000035.md) | [172](/filings/0000039263-26-000046.md) | [178](/filings/0000039263-26-000056.md) | not reported | [139](/filings/0000039263-26-000035.md) | [147](/filings/0000039263-26-000046.md) | [164](/filings/0000039263-26-000056.md) |
| Income tax | $m | [18.1 d](/filings/0000039263-26-000011.md) | [25.9](/filings/0000039263-25-000058.md) | [29.7](/filings/0000039263-25-000101.md) | [28.7](/filings/0000039263-25-000117.md) | [29.2 d](/filings/0000039263-26-000011.md) | [28.2](/filings/0000039263-26-000035.md) | [29.6](/filings/0000039263-26-000046.md) | [33.6](/filings/0000039263-26-000056.md) | [31.7 d](/filings/0000039263-26-000011.md) | [31.4](/filings/0000039263-26-000035.md) | [32.5](/filings/0000039263-26-000046.md) | [34.3](/filings/0000039263-26-000056.md) |
| Net income | $m | [103 d](/filings/0000039263-26-000011.md) | [136](/filings/0000039263-25-000058.md) | [145](/filings/0000039263-25-000101.md) | [147](/filings/0000039263-25-000117.md) | [155 d](/filings/0000039263-26-000011.md) | [151](/filings/0000039263-26-000035.md) | [157](/filings/0000039263-26-000046.md) | [174](/filings/0000039263-26-000056.md) | [166 d](/filings/0000039263-26-000011.md) | [171](/filings/0000039263-26-000035.md) | [172](/filings/0000039263-26-000046.md) | [180](/filings/0000039263-26-000056.md) |
| Diluted EPS | $ per share | not reported | [2.06](/filings/0000039263-25-000058.md) | [2.21](/filings/0000039263-25-000101.md) | [2.24](/filings/0000039263-25-000117.md) | not reported | [2.30](/filings/0000039263-26-000035.md) | [2.39](/filings/0000039263-26-000046.md) | [2.67](/filings/0000039263-26-000056.md) | not reported | [2.65](/filings/0000039263-26-000035.md) | [2.70](/filings/0000039263-26-000046.md) | [2.84](/filings/0000039263-26-000056.md) |
| Basic EPS | $ per share | not reported | [2.06](/filings/0000039263-25-000058.md) | [2.21](/filings/0000039263-25-000101.md) | [2.24](/filings/0000039263-25-000117.md) | not reported | [2.30](/filings/0000039263-26-000035.md) | [2.39](/filings/0000039263-26-000046.md) | [2.67](/filings/0000039263-26-000056.md) | not reported | [2.65](/filings/0000039263-26-000035.md) | [2.70](/filings/0000039263-26-000046.md) | [2.84](/filings/0000039263-26-000056.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $bn | [50.8](/filings/0000039263-25-000017.md) | [49.5](/filings/0000039263-24-000039.md) | [48.8](/filings/0000039263-24-000057.md) | [51.0](/filings/0000039263-24-000069.md) | [52.5](/filings/0000039263-26-000011.md) | [52.0](/filings/0000039263-25-000058.md) | [51.4](/filings/0000039263-25-000101.md) | [52.5](/filings/0000039263-25-000117.md) | [53.0](/filings/0000039263-26-000056.md) | [52.7](/filings/0000039263-26-000035.md) | [53.9](/filings/0000039263-26-000046.md) | [54.5](/filings/0000039263-26-000056.md) |
| Total liabilities | $bn | [47.1](/filings/0000039263-25-000017.md) | [45.9](/filings/0000039263-24-000039.md) | [45.2](/filings/0000039263-24-000057.md) | [46.9](/filings/0000039263-24-000069.md) | [48.6](/filings/0000039263-26-000011.md) | [47.9](/filings/0000039263-25-000058.md) | [47.2](/filings/0000039263-25-000101.md) | [48.1](/filings/0000039263-25-000117.md) | [48.5](/filings/0000039263-26-000056.md) | [48.2](/filings/0000039263-26-000035.md) | [49.3](/filings/0000039263-26-000046.md) | [50.5](/filings/0000039263-26-000056.md) |
| Shareholders' equity | $bn | [3.7](/filings/0000039263-26-000011.md) | [3.6](/filings/0000039263-25-000101.md) | [3.7](/filings/0000039263-25-000117.md) | [4.1](/filings/0000039263-25-000117.md) | [3.9](/filings/0000039263-26-000056.md) | [4.1](/filings/0000039263-26-000046.md) | [4.2](/filings/0000039263-26-000056.md) | [4.5](/filings/0000039263-26-000056.md) | [4.6](/filings/0000039263-26-000056.md) | [4.5](/filings/0000039263-26-000046.md) | [4.6](/filings/0000039263-26-000056.md) | [4.0](/filings/0000039263-26-000056.md) |

- Cash and equivalents: not reported
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(83.0) d](/filings/0000039263-26-000011.md) | [488](/filings/0000039263-25-000058.md) | [130 d](/filings/0000039263-25-000101.md) | [307 d](/filings/0000039263-25-000117.md) | [64.3 d](/filings/0000039263-26-000011.md) | [(296)](/filings/0000039263-26-000035.md) | [141 d](/filings/0000039263-26-000046.md) | [249 d](/filings/0000039263-26-000056.md) | [181 d](/filings/0000039263-26-000011.md) | [237](/filings/0000039263-26-000035.md) | [52.9 d](/filings/0000039263-26-000046.md) | [293 d](/filings/0000039263-26-000056.md) |
| Capital expenditure | $m | [40.6 d](/filings/0000039263-26-000011.md) | [38.2](/filings/0000039263-25-000058.md) | [26.6 d](/filings/0000039263-25-000101.md) | [25.3 d](/filings/0000039263-25-000117.md) | [37.6 d](/filings/0000039263-26-000011.md) | [41.0](/filings/0000039263-26-000035.md) | [26.3 d](/filings/0000039263-26-000046.md) | [36.9 d](/filings/0000039263-26-000056.md) | [42.5 d](/filings/0000039263-26-000011.md) | [38.6](/filings/0000039263-26-000035.md) | [60.1 d](/filings/0000039263-26-000046.md) | [44.0 d](/filings/0000039263-26-000056.md) |
| Dividends paid | $m | [59.8 d](/filings/0000039263-26-000011.md) | [59.8](/filings/0000039263-25-000058.md) | [59.8 d](/filings/0000039263-25-000101.md) | [61.3 d](/filings/0000039263-25-000117.md) | [61.5 d](/filings/0000039263-26-000011.md) | [61.7](/filings/0000039263-26-000035.md) | [64.9 d](/filings/0000039263-26-000046.md) | [64.7 d](/filings/0000039263-26-000056.md) | [64.1 d](/filings/0000039263-26-000011.md) | [64.0](/filings/0000039263-26-000035.md) | [64.8 d](/filings/0000039263-26-000046.md) | [65.0 d](/filings/0000039263-26-000056.md) |
| Share repurchases | $m | [2.2 d](/filings/0000039263-26-000011.md) | [2.1](/filings/0000039263-25-000058.md) | [30.2 d](/filings/0000039263-25-000101.md) | [20.0 d](/filings/0000039263-25-000117.md) | [8.6 d](/filings/0000039263-26-000011.md) | [2.6](/filings/0000039263-26-000035.md) | [0.1 d](/filings/0000039263-26-000046.md) | [69.8 d](/filings/0000039263-26-000056.md) | [85.4 d](/filings/0000039263-26-000011.md) | [72.3](/filings/0000039263-26-000035.md) | [90.9 d](/filings/0000039263-26-000046.md) | [15.2 d](/filings/0000039263-26-000056.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [64.6](/filings/0000039263-24-000039.md) | [64.4](/filings/0000039263-24-000057.md) | [64.2](/filings/0000039263-24-000069.md) | [64.4](/filings/0000039263-25-000058.md) | [64.3](/filings/0000039263-25-000101.md) | [64.1](/filings/0000039263-25-000117.md) | [64.3](/filings/0000039263-26-000035.md) | [64.4](/filings/0000039263-26-000046.md) | [64.1](/filings/0000039263-26-000056.md) | [63.1](/filings/0000039263-26-000035.md) | [62.5](/filings/0000039263-26-000046.md) | [62.1](/filings/0000039263-26-000056.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 62,180,525 at 2026-10-27, from the cover of the [10-Q filed 2026-10-29](/filings/0000039263-26-000056.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 15:38 ET. No prices; not investment advice.